Elanco Guides FY Revenue to $5.16B-$5.18B
ELAN sits 24% above its 52-week low of $19.4.
Summary
Elanco put a full-year revenue range of $5.16B-$5.18B on the table. That follows the Q2 2026 print of $1.37B in revenue, up 10%, when the company already raised full-year guidance, so this is the concrete number behind that raise. The range implies roughly $3.79B-$3.81B of revenue over the second half, which is the figure that matters for whether the growth trend holds. Q3 results have since come in at revenue of USD 1,265 Million versus an IBES estimate of USD 1,208 Million, with net income of $18M and adjusted EPS of 27c. For the fourth quarter, Elanco sees adjusted EPS of 16c-19c. No margin or cash flow detail came with the headline, so the quality of the revenue is still unproven, and any update to this range will settle whether the AHV acquisition and new launches are carrying the top line as advertised.
At the time of this announcement, ELAN was trading at $24.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $11.8B. The 52-week trading range was $19.40 to $27.98. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.